Weekly Analysts’ Ratings Updates for Intuitive Surgical (ISRG)

Several analysts have recently updated their ratings and price targets for Intuitive Surgical (NASDAQ: ISRG):

• 1/6/2023 – Intuitive Surgical had its price target raised by analysts at Morgan Stanley from $235.00 to $290.00. They now have an “equal weight” rating on the stock.
• 1/4/2023 – Intuitive Surgical had its price target raised by analysts at Barclays PLC from $235.00 to $298.00.
• 12/22/2022 – Intuitive Surgical had its price target raised by analysts at Argus from $265.00 to $320.00. They now have a “buy” rating on the stock.
• 12/20/2022 – Intuitive Surgical had its price target raised by analysts at Truist Financial Co. from $300.00 to $310.00. They now have a “buy” rating on the stock.
• 12/12/2022 – Intuitive Surgical had its price target raised by analysts at Wells Fargo & Company from $262.00 to $305.00. They now have an “overweight” rating on the stock.
• 12/12/2022 – Intuitive Surgical had its price target raised by analysts at Citigroup Inc. from $245.00 to $318.00.
• 12/5/2022 – Intuitive Surgical had its price target raised by analysts at BTIG Research from $247.00 to $316.00. They now have a “buy” rating on the stock.
• 11/18/2022 – Intuitive Surgical had its price target raised by analysts at JPMorgan Chase & Co. from $250.00 to $280.00. They now have an “overweight” rating on the stock.
• 11/14/2022 – Intuitive Surgical had its price target raised by analysts at Truist Financial Co. from $260.00 to $300.00.

Intuitive Surgical Trading Up 0.7 %

Shares of NASDAQ:ISRG opened at $270.39 on Monday. The company has a market capitalization of $95.55 billion, a price-to-earnings ratio of 71.34, a PEG ratio of 5.14 and a beta of 1.36. Intuitive Surgical, Inc. has a 12-month low of $180.07 and a 12-month high of $333.07. The business has a 50-day moving average price of $262.04 and a 200 day moving average price of $229.65.

Intuitive Surgical (NASDAQ:ISRG – Get Rating) last released its quarterly earnings results on Tuesday, October 18th. The medical equipment provider reported $0.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.91 by ($0.01). The company had revenue of $1.56 billion during the quarter, compared to analysts’ expectations of $1.52 billion. Intuitive Surgical had a net margin of 22.52% and a return on equity of 11.54%. Intuitive Surgical’s revenue was up 11.0% on a year-over-year basis. During the same period last year, the firm posted $1.04 earnings per share. As a group, equities research analysts predict that Intuitive Surgical, Inc. will post 3.77 earnings per share for the current fiscal year.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, CEO Gary S. Guthart sold 44,203 shares of Intuitive Surgical stock in a transaction dated Friday, October 21st. The stock was sold at an average price of $210.84, for a total value of $9,319,760.52. Following the completion of the transaction, the chief executive officer now directly owns 23,297 shares of the company’s stock, valued at approximately $4,911,939.48. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Intuitive Surgical news, CEO Gary S. Guthart sold 44,203 shares of the company’s stock in a transaction on Friday, October 21st. The shares were sold at an average price of $210.84, for a total value of $9,319,760.52. Following the completion of the transaction, the chief executive officer now owns 23,297 shares in the company, valued at $4,911,939.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Amal M. Johnson sold 6,375 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, November 8th. The shares were sold at an average price of $239.36, for a total value of $1,525,920.00. Following the completion of the transaction, the director now owns 11,224 shares in the company, valued at $2,686,576.64. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 66,578 shares of company stock worth $14,524,401. 0.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Intuitive Surgical

Hedge funds have recently made changes to their positions in the stock. Modera Wealth Management LLC grew its stake in Intuitive Surgical by 2.4% during the 3rd quarter. Modera Wealth Management LLC now owns 1,739 shares of the medical equipment provider’s stock valued at $326,000 after purchasing an additional 41 shares in the last quarter. ICICI Prudential Asset Management Co Ltd lifted its holdings in shares of Intuitive Surgical by 4.1% in the second quarter. ICICI Prudential Asset Management Co Ltd now owns 1,070 shares of the medical equipment provider’s stock valued at $217,000 after purchasing an additional 42 shares in the last quarter. SWS Partners boosted its holdings in shares of Intuitive Surgical by 0.9% during the third quarter. SWS Partners now owns 4,900 shares of the medical equipment provider’s stock worth $918,000 after purchasing an additional 43 shares during the period. Sepio Capital LP increased its position in Intuitive Surgical by 0.7% in the 3rd quarter. Sepio Capital LP now owns 6,673 shares of the medical equipment provider’s stock worth $1,251,000 after purchasing an additional 45 shares during the last quarter. Finally, Roundview Capital LLC increased its stake in shares of Intuitive Surgical by 0.5% during the 2nd quarter. Roundview Capital LLC now owns 9,395 shares of the medical equipment provider’s stock worth $1,886,000 after purchasing an additional 46 shares during the last quarter. Institutional investors and hedge funds own 81.96% of the company’s stock.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.